Dianthus therapeutics to participate in two upcoming investor conferences

New york and waltham, mass., feb. 26, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:
DNTH Ratings Summary
DNTH Quant Ranking